Propulsion of Osteoarthritis Pipeline as Novel and Extensive 130+ Therapies Likely to Enter in the Treatment Domain | Major Companies – GSK, Gilead Sciences, Novartis, AstraZeneca, and Others

DelveInsight’s, “Osteoarthritis Pipeline Insight 2023” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Osteoarthritis pipeline landscape. It covers the Osteoarthritis pipeline drug profiles, including Osteoarthritis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Osteoarthritis Pipeline Report

 

  • DelveInsight’s Osteoarthritis Pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis.

 

  • The leading Osteoarthritis Companies such as Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.

 

  • Promising Osteoarthritis Therapies such as V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, and others.

 

  • The Osteoarthritis Companies and academics are working to assess challenges and seek opportunities that could influence R&D Osteoarthritis. The Osteoarthritis pipeline therapies under development are focused on novel approaches to treat/improve Osteoarthritis.

 

Request a sample and discover the recent breakthroughs happening in the Osteoarthritis Pipeline landscape @ Osteoarthritis Pipeline Outlook Report

 

Osteoarthritis Overview

Osteoarthritis (OA) is the most common form of arthritis. Some people call it degenerative joint disease or “wear and tear” arthritis. It occurs most frequently in the hands, hips, and knees. Osteoarthritis is most likely to affect the joints that bear most of weight, such as the knees and feet. Joints that the person use a lot in everyday life, such as the joints of the hand, are also commonly affected. The main symptoms of osteoarthritis are pain and sometimes stiffness in the affected joints.

 

Recent Developmental Activities in the Osteoarthritis Treatment Landscape

 

  • In January 2021 Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML).

 

  • In January 2022, Astex Pharmaceuticals, Inc. announced that the European Commission (EC) has granted orphan-drug designation (ODD) to the oral fixed dose combination of decitabine and cedazuridine (ASTX727) for the treatment of Acute Myeloid Leukemia (AML).

 

  • In April 2021, Ampio Pharmaceuticals announced that it had received a positive response from the U.S. Food and Drug Administration (FDA) on its plans for its AP-013 Phase III trial for the intra-articular injection of Ampion, its novel anti-inflammatory, for patients suffering from severe osteoarthritis of the knee (OAK).

 

  • In April 2021, Biosplice Therapeutics announced the execution of a licensing agreement that grants Samil the right to develop and exclusively commercialize lorecivivint (SM04690) for the treatment of knee osteoarthritis (“OA”) in the Republic of Korea.

 

  • In April 2021, Eupraxia Pharmaceuticals announced that it has entered into an agreement (the “CTO Agreement”) with NBCD A/S (“NBCD”) to conduct Eupraxia’s EP-104IAR Phase 2 clinical trial that will initiate later this year.

 

  • In October 2020, Merck KGaA entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme. Under the terms of the deal, Merck will out-license M6495 to Novartis for further evaluation in osteoarthritis patients.

 

  • In September 2020, Sorrento Therapeutics released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) in the reduction of OsteoArthritis (OA) knee pain.

 

  • X0002 is a new anti-inflammatory drug that acts as an inhibitor of Cyclooxygenase. It is currently in the Phase III stage of development for Osteoarthritis and is being developed by Techfields Pharma.

 

  • In July 2020, the FDA granted the Fast Track Designation to X0002 for Knee Osteoarthritis and the low back. 

 

For further information, refer to the detailed Osteoarthritis Drugs Launch, Osteoarthritis Developmental Activities, and Osteoarthritis News, click here for Osteoarthritis Ongoing Clinical Trial Analysis

 

Osteoarthritis Emerging Drugs Profile

 

  • Lorecivivint: Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways and is in development as a potential disease-modifying osteoarthritis drug. Vehicle-controlled preclinical data suggest that lorecivivint has a dual mechanism of action with three potential effects on joint health: reduction of inflammation, slowing of cartilage breakdown, and generation of cartilage. The drug is currently in Phase III stage of clinical trial evaluation to treat the patients suffering from osteoarthritis

 

  • CYP 004: Cynata Therapeutics

Cynata’s CYP-004 MSC product is the subject of a Phase III clinical trial being sponsored by the University of Sydney and funded by an Australian Government National Health and Medical Research Council (NHMRC) competitive Project Grant in addition to in-kind contributions from participating institutions. Cynata will supply Cymerus MSCs for use in the trial and will not be required to contribute any cash to fund the project.  The clinical trial commenced in late 2020 and is entitled Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis (SCUlpTOR): a randomised placebo-controlled trial

 

  • JTA-004: Bone Therapeutics

JTA-004 is Bone Therapeutics’ next generation of intra-articular injectable, which is currently in phase III development for the treatment of osteoarthritic pain in the knee. Consisting of a unique patented mix of plasma proteins, hyaluronic acid – a natural component of knee synovial fluid, and a fast-acting analgesic, JTA-004 intends to provide added lubrication and protection to the cartilage of the arthritic joint and to alleviate osteoarthritic pain. In a phase II study involving 164 patients, JTA-004 showed an improved pain relief at 3 and 6 months compared to Hylan G-F 20, the global market leader in osteoarthritis treatment.

 

  • SMUP-IA-01: Medipost

​SMUP-IA-01, SMUP allogeneic umbilical cord blood-derived mesenchymal stem cells, is currently under development for the treatment and prevention of Osteoarthritis. In SMUP-IA-01’s phase I clinical trials in Korea, 12 patients with knee osteoarthritis were given a single injection into their knee joint cavity at Seoul National University Hospital. The response to the drug was then evaluated for 6 months, and the results were shown to demonstrate the safety and improvement of joint function and pain.

 

  • TTAX03: Tissue Tech

TTAX03 is a sterile, lyophilized and micronized particulate human Amniotic and umbilical cord co product manufactured using aseptic processing followed by terminal sterilization by gamma irradiation in compliance with current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP) to preserve extracellular matrices and growth factors/cytokines therein without any living cells. TTAX03 is currently being investigated in Phase II stage of development for the treatment of patients with knee osteoarthritis

 

Osteoarthritis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics

 

Find out more about the Osteoarthritis Pipeline Segmentation, Therapeutics Assessment, and Osteoarthritis Emerging Drugs @ Osteoarthritis Treatment Landscape

 

Scope of the Osteoarthritis Pipeline Report

 

  • Coverage- Global

 

  • Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.

 

  • Osteoarthritis Therapies- V120083, Naproxen, EP-104IAR, Hyalgan, SI-613, Oral Calcitonin, APPA, and others.

 

  • Osteoarthritis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Osteoarthritis Pipeline Companies and Therapies, click here @ Osteoarthritis Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Osteoarthritis Executive Summary
  3. Osteoarthritis: Overview
  4. Osteoarthritis Pipeline Therapeutics
  5. Osteoarthritis Pipeline Therapeutic Assessment
  6. Osteoarthritis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Lorecivivint: Biosplice Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. TTAX03: Tissue Tech
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. GLPG-0555: Gilead Sciences
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Protego-PD: Plakous Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Osteoarthritis Key Companies
  21. Osteoarthritis Key Products
  22. Osteoarthritis- Unmet Needs
  23. Osteoarthritis- Market Drivers and Barriers
  24. Osteoarthritis- Future Perspectives and Conclusion
  25. Osteoarthritis Analyst Views
  26. Osteoarthritis Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Osteoarthritis Mergers and acquisitions, Osteoarthritis Licensing Activities @ Osteoarthritis Emerging Drugs, and Recent Trends

 

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Posted

in

by

Tags: